Takeda Pharmaceutical Co (MEX:TAK N) Net Change in Cash : MXN17,028 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Takeda Pharmaceutical Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Takeda Pharmaceutical Co's Net Change in Cash for the three months ended in Dec. 2024 was MXN-49,475 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was MXN17,028 Mil.

Takeda Pharmaceutical Co Net Change in Cash Historical Data

The historical data trend for Takeda Pharmaceutical Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Net Change in Cash Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Net Change in Cash

Get a 7-Day Free Trial

-14,179.35

61,795.14

-19,566.71

-42,635.72

-8,389.04

Takeda Pharmaceutical Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Change in Cash	Get a 7-Day Free Trial															-3,500.56	18,769.94	40,294.94	7,438.30	-49,475.35

Takeda Pharmaceutical Co Net Change in Cash Calculation

Takeda Pharmaceutical Co's Net Change in Cash for the fiscal year that ended in Mar. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	79353.483	+	-51384.621	+	-39260.668	+	2902.766
	=	-8,389

Takeda Pharmaceutical Co's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 52033.524 + -15668.117 + -88942.918 + 3102.166

= -49,475

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN17,028 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (MEX:TAK N) » Definitions » Net Change in Cash

Comparable Companies

TSE:4507 TSE:4523 TSE:4540 TSE:4530 TSE:4506 TSE:4516 TSE:4887 TSE:4547 TSE:4521 TSE:4553 ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506

Traded in Other Exchanges

TAK:USA TKPHF:USA 4502:Japan 0A87:UK TKD:Germany TAKP34:Brazil TKD:Austria

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co Headlines

No Headlines